Slayback Pharma announces approval and immediate launch of Dexmedetomidine Hydrochloride in 0.9% Sodium Chloride Injection in 200 mcg/ 50 mL and 400 mcg/ 100 mL (4 mcg/mL) vials, generic equivalent of Precedex™ 4 mcg/ mL
Slayback Pharma announces approval of Hydroxyprogesterone Caproate Injection, USP 250 mg/ 1 mL in a single-dose vial, generic equivalent of Makena® Injection 250 mg/ 1 mL
Slayback Pharma announces launch of Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 mL in a multi-dose vial, the first generic equivalent of Makena Injection 1,250 mg/ 5 mL multi-dose vial
Slayback Pharma announces FDA approval of Hydroxyprogesterone Caproate Injection, USP 1,250 mg/ 5 mL in a multi-dose vial, the first generic equivalent of Makena® Injection 1,250 mg/ 5 mL multi-dose vial
